How The Parts Add Up: VONE Targets $274
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 22 2024
0mins
Should l Buy APLS?
Source: NASDAQ.COM
Vanguard Russell 1000 ETF Analysis: The Vanguard Russell 1000 ETF (VONE) has an implied analyst target price of $274.39, indicating a potential upside of 10.34% from its current trading price of $248.67.
Notable Holdings with Upside Potential: Key holdings within VONE, such as Apellis Pharmaceuticals (APLS), Peloton Interactive (PTON), and Intra-Cellular Therapies (ITCI), show significant upside potential based on analysts' target prices, suggesting optimism about their future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APLS
Wall Street analysts forecast APLS stock price to rise
14 Analyst Rating
9 Buy
5 Hold
0 Sell
Moderate Buy
Current: 17.230
Low
19.00
Averages
31.69
High
48.00
Current: 17.230
Low
19.00
Averages
31.69
High
48.00
About APLS
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RTW Investments Acquires Stake in Apellis Pharmaceuticals
- New Investment Position: RTW Investments initiated a new stake in Apellis Pharmaceuticals during Q4 2026 by acquiring 7,666,764 shares valued at $192.59 million, reflecting a strategic confidence in the company.
- Asset Allocation Insight: As of December 31, 2025, Apellis accounted for 1.93% of RTW's 13F reportable AUM, indicating its growing significance within the investment portfolio.
- Market Performance Review: Despite a 29% decline in Apellis's stock price over the past year, currently priced at $17.21, the company generated approximately $689 million in product revenue last year, demonstrating strong demand in the rare disease market.
- Strategic Investment Shift: RTW's portfolio is heavily weighted towards high-growth biotech firms, and the addition of Apellis is viewed as a calculated pivot towards more stable revenue streams, potentially offering investors a better risk-reward profile.
See More
RTW Investments Acquires Stake in Apellis Pharmaceuticals
- New Investment Position: RTW Investments established a new position in Apellis Pharmaceuticals by acquiring 7,666,764 shares in Q4 2026, valued at $192.59 million, reflecting confidence in the company despite its 1.93% portfolio allocation.
- Revenue Growth Potential: Apellis generated approximately $689 million in product revenue last year, with its flagship therapy contributing about $587 million, indicating strong demand and expanding market share in the rare disease sector.
- Portfolio Diversification: RTW's portfolio is heavily weighted towards high-growth biotech firms like Madrigal and Insmed, while the sub-2% stake in Apellis suggests a strategic pivot towards more stable revenue streams without sacrificing upside potential.
- Market Competitive Advantage: Apellis focuses on innovative therapies for complement-driven diseases, leveraging a robust pipeline and strategic collaborations to enhance its competitive position in the rare disease and specialty therapeutics market, despite its stock performance falling short of expectations.
See More
RTW Investments Takes New Stake in Apellis Pharmaceuticals
- New Investment Move: RTW Investments initiated a new position in Apellis Pharmaceuticals during Q4 2026, acquiring 7,666,764 shares valued at $192.59 million, indicating confidence in the biotech firm’s future prospects.
- Market Performance Analysis: Currently priced at $17.21, Apellis shares have declined 29% over the past year, significantly underperforming the S&P 500, which has risen 15% in the same period, reflecting market caution regarding its growth trajectory.
- Revenue and Growth Potential: Apellis generated approximately $689 million in product revenue last year, with its flagship therapy alone contributing about $587 million, demonstrating real demand and potential for market share expansion in the rare disease sector.
- Portfolio Strategy: Apellis accounts for 1.93% of RTW's reportable AUM, suggesting a strategic pivot towards more stable revenue streams while still maintaining exposure to high-growth opportunities within its broader investment portfolio.
See More
Roth Capital Initiates Buy on Apellis Pharmaceuticals with $31 Target
- Market Reaction Analysis: Despite a ~75% decline from its 2023 peak, Roth Capital Partners views Apellis Pharmaceuticals (APLS) as a compelling investment opportunity due to its lead asset, Syfovre, indicating market recognition of its potential.
- Stable Market Share: Analyst Adam Walsh notes that Syfovre holds about a 60% market share in geographic atrophy (GA), with injection volumes increasing by 17% in FY25, demonstrating the company's strong competitive position in this sector.
- Revenue Forecast Upgrade: Walsh projects that with accelerated adoption of Syfovre starting in FY27, particularly due to the launch of a prefilled syringe and functional imaging tools, the company's revenue will exceed market expectations, highlighting future growth potential.
- Long-term Revenue Projection: The analyst estimates that peak revenue for Syfovre could reach $1.2 billion by FY34, which is 30% above consensus, indicating significant financial growth prospects for the company in the coming years.
See More
Rising Oil Prices Trigger Inflation Concerns
- Oil Price Surge: Brent crude closed at $101.30, up 10.11%, while West Texas Intermediate finished at $96.38, up 10.46%, indicating heightened sensitivity in global markets to rising oil prices, which could lead to reduced consumer spending and impact economic growth.
- Inflation Concerns Rise: The surge in oil prices and geopolitical tensions have heightened investor worries about future inflation, driving U.S. Treasury yields higher, with the 30-year bond yield reaching 4.88% and the 10-year note at 4.26%, potentially dampening corporate investment and consumer confidence.
- Weak Stock Market Performance: All four major U.S. indices closed lower, with the Nasdaq down 1.74%, and both the Dow Jones and S&P 500 down 1.48%, while the small-cap Russell 2000 fell 2.12%, reflecting a pessimistic sentiment regarding economic prospects.
- Crypto Market Stability: Despite rising oil prices and escalating tensions in the Middle East, Bitcoin stabilized around $70,000, indicating ongoing demand for crypto assets, even as some short-term selling pressure emerged among holders, with Bitcoin continuing to outperform traditional risk assets.
See More
Apellis (APLS) Q4 2025 Earnings Call Transcript
See More
RTW Investments Acquires Stake in Apellis Pharmaceuticals
- New Investment Position: RTW Investments initiated a new stake in Apellis Pharmaceuticals during Q4 2026 by acquiring 7,666,764 shares valued at $192.59 million, reflecting a strategic confidence in the company.
- Asset Allocation Insight: As of December 31, 2025, Apellis accounted for 1.93% of RTW's 13F reportable AUM, indicating its growing significance within the investment portfolio.
- Market Performance Review: Despite a 29% decline in Apellis's stock price over the past year, currently priced at $17.21, the company generated approximately $689 million in product revenue last year, demonstrating strong demand in the rare disease market.
- Strategic Investment Shift: RTW's portfolio is heavily weighted towards high-growth biotech firms, and the addition of Apellis is viewed as a calculated pivot towards more stable revenue streams, potentially offering investors a better risk-reward profile.
See More
RTW Investments Acquires Stake in Apellis Pharmaceuticals
- New Investment Position: RTW Investments established a new position in Apellis Pharmaceuticals by acquiring 7,666,764 shares in Q4 2026, valued at $192.59 million, reflecting confidence in the company despite its 1.93% portfolio allocation.
- Revenue Growth Potential: Apellis generated approximately $689 million in product revenue last year, with its flagship therapy contributing about $587 million, indicating strong demand and expanding market share in the rare disease sector.
- Portfolio Diversification: RTW's portfolio is heavily weighted towards high-growth biotech firms like Madrigal and Insmed, while the sub-2% stake in Apellis suggests a strategic pivot towards more stable revenue streams without sacrificing upside potential.
- Market Competitive Advantage: Apellis focuses on innovative therapies for complement-driven diseases, leveraging a robust pipeline and strategic collaborations to enhance its competitive position in the rare disease and specialty therapeutics market, despite its stock performance falling short of expectations.
See More
RTW Investments Takes New Stake in Apellis Pharmaceuticals
- New Investment Move: RTW Investments initiated a new position in Apellis Pharmaceuticals during Q4 2026, acquiring 7,666,764 shares valued at $192.59 million, indicating confidence in the biotech firm’s future prospects.
- Market Performance Analysis: Currently priced at $17.21, Apellis shares have declined 29% over the past year, significantly underperforming the S&P 500, which has risen 15% in the same period, reflecting market caution regarding its growth trajectory.
- Revenue and Growth Potential: Apellis generated approximately $689 million in product revenue last year, with its flagship therapy alone contributing about $587 million, demonstrating real demand and potential for market share expansion in the rare disease sector.
- Portfolio Strategy: Apellis accounts for 1.93% of RTW's reportable AUM, suggesting a strategic pivot towards more stable revenue streams while still maintaining exposure to high-growth opportunities within its broader investment portfolio.
See More
Roth Capital Initiates Buy on Apellis Pharmaceuticals with $31 Target
- Market Reaction Analysis: Despite a ~75% decline from its 2023 peak, Roth Capital Partners views Apellis Pharmaceuticals (APLS) as a compelling investment opportunity due to its lead asset, Syfovre, indicating market recognition of its potential.
- Stable Market Share: Analyst Adam Walsh notes that Syfovre holds about a 60% market share in geographic atrophy (GA), with injection volumes increasing by 17% in FY25, demonstrating the company's strong competitive position in this sector.
- Revenue Forecast Upgrade: Walsh projects that with accelerated adoption of Syfovre starting in FY27, particularly due to the launch of a prefilled syringe and functional imaging tools, the company's revenue will exceed market expectations, highlighting future growth potential.
- Long-term Revenue Projection: The analyst estimates that peak revenue for Syfovre could reach $1.2 billion by FY34, which is 30% above consensus, indicating significant financial growth prospects for the company in the coming years.
See More
Rising Oil Prices Trigger Inflation Concerns
- Oil Price Surge: Brent crude closed at $101.30, up 10.11%, while West Texas Intermediate finished at $96.38, up 10.46%, indicating heightened sensitivity in global markets to rising oil prices, which could lead to reduced consumer spending and impact economic growth.
- Inflation Concerns Rise: The surge in oil prices and geopolitical tensions have heightened investor worries about future inflation, driving U.S. Treasury yields higher, with the 30-year bond yield reaching 4.88% and the 10-year note at 4.26%, potentially dampening corporate investment and consumer confidence.
- Weak Stock Market Performance: All four major U.S. indices closed lower, with the Nasdaq down 1.74%, and both the Dow Jones and S&P 500 down 1.48%, while the small-cap Russell 2000 fell 2.12%, reflecting a pessimistic sentiment regarding economic prospects.
- Crypto Market Stability: Despite rising oil prices and escalating tensions in the Middle East, Bitcoin stabilized around $70,000, indicating ongoing demand for crypto assets, even as some short-term selling pressure emerged among holders, with Bitcoin continuing to outperform traditional risk assets.
See More
Apellis (APLS) Q4 2025 Earnings Call Transcript
See More
